Showing 1551-1560 of 1644 results for "".
- Women With Migraine May Have a Higher Risk of Pregnancy Complicationshttps://practicalneurology.com/news/women-with-migraine-may-have-a-higher-risk-of-pregnancy-complications/2469844/According to a preliminary study, women with migraine may have a higher risk of pregnancy complications (eg, gestational hypertension, preterm delivery, and preeclampsia). Among women with migraine, the presence of aura was associated with a 51% higher risk of preeclampsia compared with a 29% hig
- Validation of Artificial Intelligence-Assisted Imaging for Strokehttps://practicalneurology.com/news/validation-of-artificial-intelligence-assisted-imaging-for-stroke/2469822/Data from several new studies presented at the American Heart Association International Stroke Conference validate the sensitivity and specificity of an artificial intelligence-assisted imaging system (Viz LVO and Viz LCH; Viz.ai, San Francisco, CA) for evaluation of stroke in real-world settings
- Relative Ischemic Lesion Growth Decreased More with nVNS for Treatment of Acute Strokehttps://practicalneurology.com/news/relative-ischemic-lesion-growth-decreased-more-with-nvns-for-treatment-of-acute-stroke/2469819/Data presented at the American Heart Associations’ 2022 International Stroke Conference suggests safety and feasibility of noninvasive vagus nerve stimulation (nVNS)(electroCore, Rockaway, NJ) in the acute treatment of stroke. The randomized sham-controlled study TR-VENUS (
- FDA Accepts Priority Review Application for Fenfluramine for Lennox-Gastaut Seizureshttps://practicalneurology.com/news/fda-accepts-priority-review-application-for-fenfluramine-for-lennox-gastaut-seizures/2469762/The Food and Drug Administration (FDA) has accepted for filing and granted priority review to a supplemental New Drug Application (sNDA) for the use of fenfluramine (Fintepla; Zogenix, Emeryville, CA) for seizures associated with Lennox-Gastaut syndrome (LGS). The FDA granted priority review with
- National Treatment and Diagnostic Alzheimer Disease Registry Announcedhttps://practicalneurology.com/news/national-treatment-and-diagnostic-alzheimer-disease-registry-announced/2469739/Launch of a new national registry to collect real-world evidence on the diagnosis, treatment, and outcomes in Alzheimer disease (AD) has been announce. The registry is a joint initiative of The Alzheimer’s Association; the American College of Radiology; the American Society of Neuroradiolog
- Retrospective Study Shows Ischemic Stroke and Atrial Fibrillation Linked in Timehttps://practicalneurology.com/news/retrospective-study-shows-ischemic-stroke-and-atrial-fibrillation-linked-in-time/2469709/As published in JAMA Cardiology, data from continuous rhythm monitoring devices showed atrial fibrillation (AF) was directly and transiently associated in time with ischemic strokes. Among 891 people who had an ischemic stroke during continuous cardiac monitoring, 76.5% had no
- Fenfluramine Indication Expansion to Include Lennox-Gastaut Syndrome Submitted to FDAhttps://practicalneurology.com/news/fenfluramine-indication-expansion-to-include-lennox-gastaut-syndrome-submitted-to-fda/2469704/A supplemental new drug application (sNDA) has been submitted to the Food and Drug Administration (FDA) for fenfluramine (Fintepla; Zogenix, Emeryville, CA) to treat seizures associated with Lennox-Gastaut Syndrome (LGS). In a randomized controlled phase 3 clinical trial (
- Lecanemab, an Antibody to Amyloid Beta, Reduced Amyloid Levels and Cognitive Declinehttps://practicalneurology.com/news/lecanemab-an-antibody-to-amyloid-beta-reduced-amyloid-levels-and-cognitive-decline/2469653/Preliminary assessment of results clinical trials of lecanemab (BAN2401; Biogen, Cambridge, MA; Eisai, Tokyo, Japan) for potential treatment of Alzheimer disease (AD), were presented at the Alzheimer’s Association International Conference July 26-30, 2021. Lecanemab reduced brain
- Cases of Dementia Projected to Increase Worldwidehttps://practicalneurology.com/news/cases-of-dementia-projected-to-increase-worldwide/2469646/Data presented at the Alzheimer's Association International Congress July 26-30, 2021 show that all types of dementia have been on the rise in recent years and are predicted to increase further. Rates of early-onset dementia are also increasing, and in the US, mortality from Alzheimer diseae
- Wrist-Worn Neuromodulation Device Cost Effective for Essential Tremorhttps://practicalneurology.com/news/wrist-worn-neuromodulation-device-cost-effective-for-essential-tremor/2469601/According to data from a retrospective analysis, the wrist-worn neuromodulation device (Cala Trio; Cala Health, Inc, Burlingame, CA) is a cost-saving treatment option for individuals with essential tremor (ET). The analysis demonstrates that ET is associated with substantial health care resource